Evidence map›Paper›PMID 38674104›Full record

ArticleInternational journal of molecular sciences2024

A Proximity Complementation Assay to Identify Small Molecules That Enhance the Traffic of ABCA4 Misfolding Variants.

Davide Piccolo, Christina Zarouchlioti, James Bellingham, Rosellina Guarascio, Kalliopi Ziaka, Robert S Molday, Michael E Cheetham

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Davide PiccoloUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.ORCID 0000-0001-5867-5383
Christina ZarouchliotiUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.ORCID 0000-0002-5096-177X
James BellinghamUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.ORCID 0000-0003-3368-5221
Rosellina GuarascioUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.ORCID 0009-0007-5989-2962
Kalliopi ZiakaUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.ORCID 0000-0002-5853-2099
Robert S MoldayDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.ORCID 0000-0002-4479-1831
Michael E CheethamUCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.
University College London · GBUniversity of British Columbia · CA

Funding

European Commission Horizon 2020 813490Macular Disease Society 23-RG-01Wellcome Trust
6 · The paper itself

Abstract

ABCA4-related retinopathy is the most common inherited Mendelian eye disorder worldwide, caused by biallelic variants in the ATP-binding cassette transporter ABCA4. To date, over 2200 ABCA4 variants have been identified, including missense, nonsense, indels, splice site and deep intronic defects. Notably, more than 60% are missense variants that can lead to protein misfolding, mistrafficking and degradation. Currently no approved therapies target ABCA4. In this study, we demonstrate that ABCA4 misfolding variants are temperature-sensitive and reduced temperature growth (30 °C) improves their traffic to the plasma membrane, suggesting the folding of these variants could be rescuable. Consequently, an in vitro platform was developed for the rapid and robust detection of ABCA4 traffic to the plasma membrane in transiently transfected cells. The system was used to assess selected candidate small molecules that were reported to improve the folding or traffic of other ABC transporters. Two candidates, 4-PBA and AICAR, were identified and validated for their ability to enhance both wild-type ABCA4 and variant trafficking to the cell surface in cell culture. We envision that this platform could serve as a primary screen for more sophisticated in vitro testing, enabling the discovery of breakthrough agents to rescue ABCA4 protein defects and mitigate ABCA4-related retinopathy.

Indexed as

ATP-Binding Cassette TransportersProtein FoldingProtein TransportCell MembraneHEK293 CellsHumansSmall Molecule LibrariesABCA4 protein, humanATP-Binding Cassette TransportersSmall Molecule LibrariesABCA4ABCA4-related retinopathyfolding correctorsmissense variantsplasma membrane proteinprotein misfoldingprotein mistraffickingStargardt disease

Identifiers

PMID38674104
PMCPMC11050442
OpenAlexW4395000432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.